Business Context and Reporting Period
This Form 8-K was filed by Aptevo Therapeutics Inc. on May 26, 2022, regarding a listing compliance matter with The Nasdaq Stock Market LLC. The company is incorporated in Delaware and trades under the symbol APVO on The Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses solely on the company's stockholders' equity status relative to Nasdaq listing requirements.
Material Changes and Events
- Nasdaq Non-Compliance: The company previously received notice of non-compliance with Nasdaq Listing Rule 5550(b)(1), which mandates a minimum of $2,500,000 in stockholders' equity.
- Compliance Plan: Aptevo submitted a plan to regain compliance by the May 16, 2022 deadline.
- Extension Granted: Nasdaq granted the company an extension through September 28, 2022, to evidence full compliance with the equity requirement.
Outlook, Risks, and Management Commentary
The primary risk identified is the potential delisting from The Nasdaq Capital Market if the company fails to meet the minimum stockholders' equity requirement by the September 28, 2022 deadline. Management has secured a temporary extension to address this deficiency.
Investor Verification Checklist
- Verify the company's current stockholders' equity balance to assess progress toward the $2,500,000 threshold.
- Monitor upcoming filings for evidence of compliance submitted by the September 28, 2022 deadline.
- Review the specific details of the compliance plan submitted to Nasdaq to understand the proposed method for raising equity.